Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d5/0f/11/d50f110c-13c9-ef8a-ce1b-aa572924cd22/mza_3951954547589852292.jpg/600x600bb.jpg
LifeLines by Biocom California
Biocom California
10 episodes
2 days ago
Candid one-on-one conversations with life science leaders in California and beyond.
Show more...
Life Sciences
Science
RSS
All content for LifeLines by Biocom California is the property of Biocom California and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Candid one-on-one conversations with life science leaders in California and beyond.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/37201488/37201488-1680647568656-fb187a50e4e87.jpg
Episode 6: Landing Multi-Million Dollar Partnerships for Next-Gen Gene Therapies While Addressing Gender Parity in Life Science Leadership
LifeLines by Biocom California
18 minutes 42 seconds
2 years ago
Episode 6: Landing Multi-Million Dollar Partnerships for Next-Gen Gene Therapies While Addressing Gender Parity in Life Science Leadership

How does a biotech startup manage to forge $125 million in partnerships with AbbVie and Eli Lilly in just under two years post-inception? Our next guest, Peter Anastasiou, CEO of Capsida Biotherapeutics since 2022, attributes much of the company's rise to addressing unmet patient needs. First invented by Viviana Gradinaru, director of the Center for Molecular and Cellular Neuroscience at the Chen Institute for Neuroscience at the California Institute of Technology, Capsida’s next-generation gene therapy platform engineers the capsids in adeno-associated viruses, or AAVs. The company uses this technology to develop treatments that are being researched for central nervous system and eye disorders. 
On this episode, we delve more into Capsida’s technology—which manipulates the amino acid sequence on the surface of the AAV, and identifies and engineers capsids (the protein surrounding a virus) that can cross the blood-brain barrier in significant amounts in order to ferry medication to where it’s needed in the body.

A key principle of life science success is embracing a diverse leadership team, and Peter is a longtime advocate of gender parity at the leadership level and has been honored for his mentoring contributions—he was named the Honorable Mentor by the Healthcare Businesswomen’s Association in 2019. His dedication to mentoring women is not only personally important to him as a father of two daughters, he says it makes the most business sense in addition to being the right thing to do. “The idea of trying to conquer such daunting challenges that we do in biotech…with a basically homogeneous group of people trying to solve that problem…it's never going to happen,” he says. “The only way to solve the challenges is by bringing the best minds around the table.”

Learn more about Capsida Biotherapeutics and Peter Anastasiou.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or joining us on this podcast? Email podcast@biocom.org.

Host: Chris Conner
Executive Producer: Marie Tutko
Senior Producer: Vincenzo Tarantino
Associate Producer: Lauren Panetta
Program & Research Coordinator: Katy Burgess
Transcripts By: Jessica Schneider
Senior Director of Marketing: Heather Ramsay
Graphic Design By: Raquel Papike

LifeLines by Biocom California
Candid one-on-one conversations with life science leaders in California and beyond.